EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Elevated Blood Bicarbonate Levels and Long-Term Adverse Outcomes in Patients with Chronic Heart Failure

Tomofumi Misaka iD, Yu Sato, Yukiko Sugawara, Ryo Ogawara, Shohei Ichimura, Yusuke Tomita, Fumiya Anzai, Tetsuro Yokokawa, Akihiko Sato, Takeshi Shimizu, Takamasa Sato, Masayoshi Oikawa und 3 weitere

ESC Heart Failure · 2024

DOI: 10.1002/ehf2.14900 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, 2024. Verfasst von Tomofumi Misaka und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Fukushima Medical University, Fukushima, Japan. Hauptthemen laut MEDLINE: Heart Failure, Bicarbonates. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science KAKENHI, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The bicarbonate (HCO3−) buffer system is crucial for maintaining acid–base homeostasis and blood pH. Recent studies showed that elevated serum HCO3− levels serve as an indicator of the beneficial effects of acetazolamide in improving decongestion in acute heart failure. In this study, we sought to clarify the clinical relevance and prognostic impact of HCO3− in chronic heart failure (CHF).

Methods

This cohort study enrolled 694 hospitalized patients with CHF (mean age 68.6 ± 14.6, 62% male) who underwent arterial blood sampling and exhibited neutral pH ranging from 7.35 to 7.45. We characterized the patients based on HCO3− levels and followed them to register cardiac events.

Results

Among the patients, 17.3% (120 patients) had HCO3− levels exceeding 26 mmol/L. Patients presenting HCO3− > 26 mmol/L were more likely to use loop diuretics and had higher serum sodium and lower potassium levels, but left ventricular ejection fraction did not differ compared with those with HCO3− between 22 and 26 (379 patients) or those with HCO3− < 22 mmol/L (195 patients). During a median follow-up period of 1950 days, Kaplan–Meier analysis revealed that patients with HCO3− > 26 mmol/L had the lowest event-free survival rate from either cardiac deaths or heart failure-related rehospitalization (P < 0.01 and 0.03, respectively). In the multivariable Cox model, the presence of HCO3− > 26 mmol/L independently predicted increased risks of each cardiac event with a hazard ratio of 2.31 and 1.69 (P < 0.01 and 0.02, respectively), while HCO3− < 22 mmol/L was not associated with these events (hazard ratios, 0.99 and 1.19; P = 0.98 and 0.43, respectively).

Conclusions

Elevated blood HCO3− levels may signify enhanced proximal nephron activation and loop diuretic resistance, leading to long-term adverse outcomes in patients with CHF, even within a normal pH range.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureBicarbonatesHumansMaleFemaleAgedPrognosisFollow-Up StudiesChronic DiseaseStroke VolumeTime FactorsBiomarkersSurvival RateRetrospective StudiesVentricular Function, LeftMiddle Aged

Stichwörter der Autor:innen

acid–base homeostasisbicarbonatebiomarkerheart failureprognosis

Substanzen

BicarbonatesBiomarkers

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Fukushima Medical University, Fukushima, Japan.
  • Department of Community Cardiovascular Medicine, Fukushima Medical University, Fukushima, Japan.
  • Department of Clinical Laboratory Sciences, Fukushima Medical University School of Health Sciences, Fukushima, Japan.

ORCID-Profile: Tomofumi Misaka

Förderung

  • Japan Society for the Promotion of Science KAKENHI
  • Japan Society for the Promotion of Science

Zitieren

APA

Misaka, T., Sato, Y., Sugawara, Y., Ogawara, R., Ichimura, S., Tomita, Y., Anzai, F., Yokokawa, T., Sato, A., Shimizu, T., Sato, T., Oikawa, M., Kobayashi, A., Yoshihisa, A., & Takeishi, Y. (2024). Elevated Blood Bicarbonate Levels and Long-Term Adverse Outcomes in Patients with Chronic Heart Failure. ESC Heart Failure. https://doi.org/10.1002/ehf2.14900

Vancouver

Misaka T, Sato Y, Sugawara Y, Ogawara R, Ichimura S, Tomita Y, et al. Elevated Blood Bicarbonate Levels and Long-Term Adverse Outcomes in Patients with Chronic Heart Failure. ESC Heart Failure. 2024. doi:10.1002/ehf2.14900

BibTeX
@article{Misaka2024,
  author = {Misaka, Tomofumi and Sato, Yu and Sugawara, Yukiko and Ogawara, Ryo and Ichimura, Shohei and Tomita, Yusuke and Anzai, Fumiya and Yokokawa, Tetsuro and Sato, Akihiko and Shimizu, Takeshi and Sato, Takamasa and Oikawa, Masayoshi and Kobayashi, Atsushi and Yoshihisa, Akiomi and Takeishi, Yasuchika},
  title = {Elevated Blood Bicarbonate Levels and Long-Term Adverse Outcomes in Patients with Chronic Heart Failure},
  journal = {ESC Heart Failure},
  year = {2024},
  doi = {10.1002/ehf2.14900}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche